TechMARK movers: SkyePharma up on study results

Related Companies

Related Indices

Related Sectors

News for Spread Betters

PreviousPrevious
NextNext

There's a new Investor Edition of CMC Markets' spread betting platform... and it's exclusive to DigitalLook.com users...

Get full details about Marketmaker:Investor Edition here. Advertisement

Date: Thursday 03 Jul 2008

LONDON (ShareCast) - Pharmaceutical firm SkyePharma was today's top riser after it said its third Phase III efficacy study evaluating Flutiform, which treats asthma, has met its primary endpoints.

"This is the third of the core clinical efficacy trials to meet its primary endpoints. These studies together with the Phase III safety study have included a total of 1,861 patients," said the group.

SkyePharma is now waiting for the one remaining clinical efficacy trial required for the US filing.

"This is being conducted by Kos Life Sciences (a wholly owned subsidiary of Abbott), and is on track to be fully recruited in July and completed in the second half of this year," it added.

FTSE TechMARK - Risers
Skyepharma (SKP) 6.40p +12.28%
Inion (IIN) 8.00p +6.67%
Trafficmaster (TFC) 32.25p +2.38%
Elan Corporation (ELA) € 22.65 +2.03%
Innovation Group (TIG) 17.25p +1.47%
Alphameric (ALM) 18.00p +1.41%
Filtronic (FTC) 72.75p +1.39%
Ark Therapeutics (AKT) 55.75p +1.36%
Computacenter (CCC) 119.50p +0.84%
Anite Group (AIE) 41.25p +0.61%

FTSE TechMARK - Fallers
Plasmon (PLM) 3.75p -14.38%
Corin Group (CRG) 127.25p -12.24%
NXT (NTX) 13.50p -8.47%
ARC International (ARK) 19.75p -8.14%
Triad Group (TRD) 18.50p -7.50%
Renovo Group (RNVO) 35.00p -7.28%
Oxford Instruments (OXIG) 233.00p -6.80%
Endeavors (END) 1.35p -5.59%
Oxford Biomedica (OXB) 20.00p -4.76%
Vernalis (VER) 4.50p -4.46%

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).